GSK’s tribulations continue
Two days ago GSK canned lete-cel. Now it is ditching otilimab, and daprodustat’s future is looking dicey.
Roche sets the gantenerumab expectations
Graduate 1 and 2 data are “not yet in house”, but a pooled analysis beckons in the event of one study failing.
Lecanemab can; now the wait for details begins
Eisai is rewarded for doubling down on lecanemab with an apparent win that endorses 20 years of research.
Unpacking Royalty Pharma
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
The year of the small buyout
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
In a quiet year for takeouts, who was buying?
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.